head and neck cancer
FDA Accepts Cue Biopharma's IND for CUE-102 in WT1-Expressing Cancers
This will be Cue's second precision therapeutic developed on its modular IL-2-based fusion protein platform that it is advancing into Phase I trials.
BeiGene Updates Phase III Data, Biomarker Analysis for Anti-PD-1 Drug in Nasopharyngeal Cancer
The analysis suggests tislelizumab plus chemo may be a first-line option for advanced patients, with a certain biomarker subgroup deriving the greatest benefit.
PDS Biotechnology Nets $1.2M Through NJ Economic Development Program to Advance Oncology Candidates
The firm sold its net operating loss tax benefits for cash proceeds under the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program.
The firm has submitted data to the Centers for Medicare and Medicaid Services' MolDx program to pursue reimbursement.
Mayo Clinic Exploring PDS Biotech's PDS0101, Merck's Keytruda in HPV-Associated Oropharyngeal Cancer
The investigator-initiated study will evaluate PDS0101 with or without Keytruda prior to surgery in oropharyngeal cancer patients at high risk of recurrence.
Aug 19, 2021
Feb 12, 2021